Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma-Reference-Cited by-同舟云学术

Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma

Published:2015 Issue:24 Volume:54 Page:3185-3188
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Tsukita Yoko¹,Fukuhara Tatsuro¹,Kobayashi Maki¹,Morita Mami¹,Suzuki Aya¹,Watanabe Kana¹,Noguchi Tetsuya²,Kurata Yasuko³,Suno Manabu⁴,Maemondo Makoto¹

Affiliation:

1. Department of Respiratory Medicine, Miyagi Cancer Center, Japan

2. Department of Gastrointestinal Medicine, Miyagi Cancer Center, Japan

3. Department of Pharmacy, Okayama University Hospital, Japan

4. Center for the Development of Medical and Health Care Education, Okayama University, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/54/24/54_54.4996/_pdf

Reference17 articles.

1. 1. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703, 2010.

2. 2. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 6: 942-946, 2011.

3. 3. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30: 863-870, 2012.

4. 4. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML₄-ALK fusion gene. Ann Surg Oncol 17: 889-897, 2010.

5. 5. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368: 2385-2394, 2013.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Crizotinib inhibits the metabolism of tramadol by non-competitive suppressing the activities of CYP2D1 and CYP3A2;PeerJ;2024-05-30

2. Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma;Internal Medicine;2019-09-15

3. Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing;Lung Cancer;2019-02

4. A systematic review of non-standard dosing of oral anticancer therapies;BMC Cancer;2018-11-22

5. Crizotinib-induced erosive esophagitis in a pediatric patient with neuroblastoma;Journal of Oncology Pharmacy Practice;2018-01-22